Performance analysis of Lineage Cell Therapeutics (LCTX)
Annual Return
Over the past 3 years, LCTX has had an average annual return of -2.99%, underperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, LCTX has had an average annual return of -15.90%, underperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, LCTX has had an average annual return of -6.82%, underperforming the benchmark SPY, which returned +15.44% annual.
Since Nov 1, 1999, LCTX has had an average annual return of -6.07%, underperforming the benchmark SPY, which returned +8.56% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.84% | +232.32% | -53.89% | -6.86% | -52.24% | +39.20% | +97.78% | -2.51% | -51.47% | -40.44% | +3.55% | +9.92% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
| +3.62% | +14.64% | -45.95% | -30.25% | +96.92% | +138.99% | +331.52% | +55.02% | -14.64% | -79.47% | +9.37% | -10.94% |
| 2002 | 2001 | 2000 | 1999 | ||||||||
| -66.31% | -38.67% | -15.49% | +3.64% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.40% | +29.75% | -17.72% | -4.44% | -11.90% | -9.39% | -27.84% | ||||||
| 2025 | +19.52% | -6.57% | -19.52% | +10.44% | +33.21% | +36.53% | +12.43% | +14.74% | +44.42% | +13.61% | -8.33% | -5.10% | +232.32% |
| 2024 | -14.67% | +11.85% | +42.25% | -26.35% | -8.24% | -0.25% | +3.26% | -14.16% | +2.38% | -8.16% | -31.42% | -11.84% | -53.89% |
| 2023 | +24.77% | -7.55% | +11.14% | -9.34% | -7.35% | +11.88% | +8.54% | -13.74% | -10.62% | -3.35% | -13.85% | +10.96% | -6.86% |
| 2022 | -35.52% | -10.77% | +9.22% | -20.77% | +2.45% | +26.40% | +3.79% | -14.02% | -19.84% | +22.10% | +5.08% | -19.29% | -52.24% |
| 2021 | +25.55% | +4.09% | +2.16% | +16.59% | -13.51% | +20.27% | -7.71% | -4.19% | +0% | -9.53% | -0.87% | +8.40% | +39.20% |
| 2020 | +15.75% | -1.98% | -17.79% | +2.38% | +3.75% | -1.30% | -5.78% | +11.58% | +2.37% | +17.48% | +29.99% | +23.07% | +97.78% |
| 2019 | +54.43% | -14.87% | +9.13% | -5.30% | -20.18% | +11.13% | +0% | -15.46% | +5.34% | -20.42% | +15.44% | -1.13% | -2.51% |
| 2018 | +35.35% | -9.98% | +2.70% | -19.70% | +3.67% | -8.03% | +26.23% | +5.77% | -14.54% | -17.04% | -16.17% | -36.17% | -51.47% |
| 2017 | -13.29% | +3.84% | +6.14% | -1.44% | -11.48% | +4.64% | -14.29% | +8.52% | -3.08% | -15.49% | +11.68% | -19.78% | -40.44% |
Drawdown analysis of Lineage Cell Therapeutics (LCTX)
The maximum drawdown for the LCTX was -99.00%, occurring on Aug 28, 2006. This drawdown has not yet recovered.
The current LCTX drawdown is -91.00%.
Since Nov 1, 1999 LCTX has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.00% | Feb 24, 2000 | 1636 | Aug 28, 2006 | Ongoing | Ongoing | Ongoing |
| -30.10% | Nov 8, 1999 | 40 | Jan 5, 2000 | 14 | Jan 26, 2000 | 54 |
| -15.38% | Jan 26, 2000 | 3 | Jan 31, 2000 | 14 | Feb 18, 2000 | 17 |
| -3.66% | Nov 1, 1999 | 1 | Nov 2, 1999 | 1 | Nov 3, 1999 | 2 |